132 related articles for article (PubMed ID: 8442095)
1. Protection against graft-versus-host disease by large doses of donor CD4+ T cells: a novel approach to bone marrow transplantation.
Heath WR; Miller JF; Sprent J
Transplant Proc; 1993 Feb; 25(1 Pt 2):1222-4. PubMed ID: 8442095
[No Abstract] [Full Text] [Related]
2. Selective inhibition of CD4 graft-versus-host activity in IL-2-treated mice.
Sykes M; Abraham VS; Harty MW; Pearson DA
Transplant Proc; 1993 Feb; 25(1 Pt 2):1225-6. PubMed ID: 8442096
[No Abstract] [Full Text] [Related]
3. Peripheral tolerance specific for host minor histocompatibility antigens in acute GVHR-protected mice is associated with functional deletion of CD4+ but not CD8+ T cells and an active suppressive mechanism.
Miconnet I; Bruley-Rosset M; Halle-Pannenko O
Transplant Proc; 1993 Feb; 25(1 Pt 1):327-8. PubMed ID: 8438320
[No Abstract] [Full Text] [Related]
4. LF 08-0299 protects murine recipients of minor antigen disparate donor bone marrow from lethal graft-versus-host disease.
Bruley-Rosset M; Churaqui E; Annat J; Dutartre P
Transplant Proc; 1996 Dec; 28(6):3114-6. PubMed ID: 8962208
[No Abstract] [Full Text] [Related]
5. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
Johnson BD; Drobyski WR; Truitt RL
Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
[TBL] [Abstract][Full Text] [Related]
6. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
7. Immunological mechanisms governing tolerance to self-major histocompatibility complex antigens after bone marrow transplantation.
Hess AD; Fischer AC; Horwitz LR; Bright EC; Hess JM
Transplant Proc; 1995 Feb; 27(1):1370-3. PubMed ID: 7878915
[No Abstract] [Full Text] [Related]
8. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
[TBL] [Abstract][Full Text] [Related]
9. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
Li JM; Waller EK
Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
[TBL] [Abstract][Full Text] [Related]
10. Prevention of graft-versus-host disease by a novel immunosuppressant, (5R)-5-hydroxytriptolide (LLDT-8), through expansion of regulatory T cells.
Tang W; Yang Y; Zhang F; Li YC; Zhou R; Wang JX; Zhu YN; Li XY; Yang YF; Zuo JP
Int Immunopharmacol; 2005 Dec; 5(13-14):1904-13. PubMed ID: 16275625
[TBL] [Abstract][Full Text] [Related]
11. Low-dose heparin inhibits acute graft versus host disease in mice.
Naparstek E; Slavin S; Weiss L; Sidi H; Ohana M; Reich S; Vlodavsky I; Cohen IR; Naparstek Y
Bone Marrow Transplant; 1993 Sep; 12(3):185-9. PubMed ID: 8241974
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous protection against allograft rejection and graft-versus-host disease after total lymphoid irradiation: role of natural killer T cells.
Liu YP; Li Z; Nador RG; Strober S
Transplantation; 2008 Feb; 85(4):607-14. PubMed ID: 18347541
[TBL] [Abstract][Full Text] [Related]
13. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
[TBL] [Abstract][Full Text] [Related]
14. Both class I and class II responsive T cell subsets can separately initiate lethal graft-versus-host disease in H-2-incompatible murine radiation chimeras.
Carmody L; Atkinson K; Cooley M; Chapman G; Biggs J; McKenzie I
Transplant Proc; 1987 Apr; 19(2):2876-8. PubMed ID: 3105125
[No Abstract] [Full Text] [Related]
15. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
16. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia.
Trenado A; Charlotte F; Fisson S; Yagello M; Klatzmann D; Salomon BL; Cohen JL
J Clin Invest; 2003 Dec; 112(11):1688-96. PubMed ID: 14660744
[TBL] [Abstract][Full Text] [Related]
17. Retention of graft-versus-leukemia using selective depletion of CD8-positive T lymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia.
Champlin R; Jansen J; Ho W; Gajewski J; Nimer S; Lee K; Territo M; Winston D; Tricot G; Reichert T
Transplant Proc; 1991 Feb; 23(1 Pt 2):1695-6. PubMed ID: 1899162
[No Abstract] [Full Text] [Related]
18. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
Li JM; Gorechlad J; Larsen CP; Waller EK
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
[TBL] [Abstract][Full Text] [Related]
19. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
Johnson BD; Becker EE; LaBelle JL; Truitt RL
J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
[TBL] [Abstract][Full Text] [Related]
20. An MHC-compatible allogeneic bone marrow donor with a distinct role of T cell subsets in graft-versus-leukemia effect and lethal graft-versus-host disease.
Aizawa S; Kamisaku H; Sado T
Bone Marrow Transplant; 1995 Oct; 16(4):603-9. PubMed ID: 8528179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
